Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Malignant Lymphoma

  Free Subscription


15.06.2026

2 Am J Clin Pathol
3 Am J Hematol
2 Blood
1 Bone Marrow Transplant
3 Haematologica
1 Hum Pathol
2 J Clin Oncol
3 Leuk Lymphoma
2 Leukemia


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. TORABI A, Fromm JR, Dorer R, Ding Y, et al
    CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review.
    Am J Clin Pathol. 2026;165:aqag060.
    PubMed         Abstract available

  2. ELTAHIR M, Young K, Younes S, Zhao S, et al
    Utility of ultrasensitive, US Food and Drug Administration-approved kappa and lambda dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas.
    Am J Clin Pathol. 2026;165:aqag043.
    PubMed         Abstract available


    Am J Hematol

  3. CHAVEZ JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, et al
    A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.
    Am J Hematol. 2026 Jun 12. doi: 10.1002/ajh.70403.
    PubMed         Abstract available

  4. SHENG L, Hu H, Lai Y, Wang S, et al
    CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib-Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET-CT.
    Am J Hematol. 2026 Jun 9. doi: 10.1002/ajh.70402.
    PubMed         Abstract available

  5. YUAN X, Luo Q, Huang Y, Li C, et al
    Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.
    Am J Hematol. 2026 Jun 7. doi: 10.1002/ajh.70396.
    PubMed         Abstract available


    Blood


  6. Grabow S, Delbridge ARD, Valente LJ, Strasser A. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood. 2014;124(26):3939-3946.
    Blood. 2026;147:2988.
    PubMed        

  7. YU C, Holloman M, Kim A, Chang Y, et al
    Differential role of CREBBP missense and truncating mutations in germinal center development and lymphomagenesis.
    Blood. 2026;147:2713-2727.
    PubMed         Abstract available


    Bone Marrow Transplant

  8. DACHY G, Mooyaart JE, Gabellier L, Yakoub-Agha I, et al
    Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.
    Bone Marrow Transplant. 2026 Jun 6. doi: 10.1038/s41409-026-02925.
    PubMed         Abstract available


    Haematologica

  9. STUVER R, Moore ZR, Barta SK, Bhansali RS, et al
    Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.
    Haematologica. 2026 Jun 11. doi: 10.3324/haematol.2026.300853.
    PubMed         Abstract available

  10. GUIRAUD V, Bravetti C, Guihot A, Denis JA, et al
    Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma.
    Haematologica. 2026 Jun 11. doi: 10.3324/haematol.2026.300851.
    PubMed         Abstract available

  11. STANCHINA MD, Alderuccio JP
    T-cell engagement in practice: bispecifics in large B-cell lymphoma.
    Haematologica. 2026 Jun 11. doi: 10.3324/haematol.2026.301265.
    PubMed         Abstract available


    Hum Pathol

  12. WANG WJ, Khoury JD, Fang H, Medeiros LJ, et al
    Practical approaches to the diagnosis and differential diagnosis of T-lymphoblastic leukemia/lymphoma.
    Hum Pathol. 2026 Jun 4:106198. doi: 10.1016/j.humpath.2026.106198.
    PubMed         Abstract available


    J Clin Oncol

  13. WILSON MR, Lewis KL, Kirkwood AA, Cwynarski K, et al
    High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
    J Clin Oncol. 2026 Jun 11:JCO2600947. doi: 10.1200/JCO-26-00947.
    PubMed         Abstract available

  14. FRIEDBERG JW
    End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2026 Jun 11:JCO2601188. doi: 10.1200/JCO-26-01188.
    PubMed        


    Leuk Lymphoma

  15. HEROLD S, Wieber C, Acker F, Liebers N, et al
    Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysis.
    Leuk Lymphoma. 2026 Jun 10:1-10. doi: 10.1080/10428194.2026.2682281.
    PubMed         Abstract available

  16. CHERNG HJ, DeStephano D, Gould P, Sabatino D, et al
    Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.
    Leuk Lymphoma. 2026 Jun 7:1-12. doi: 10.1080/10428194.2026.2678414.
    PubMed         Abstract available

  17. SHAN Y, Chen X, Li D, Zhang W, et al
    Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series.
    Leuk Lymphoma. 2026 Jun 7:1-8. doi: 10.1080/10428194.2026.2656946.
    PubMed         Abstract available


    Leukemia

  18. FENNELL E, Law SC, Dowell AC, Pugh MR, et al
    Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Leukemia. 2026 Jun 10. doi: 10.1038/s41375-026-02994.
    PubMed         Abstract available

  19. FLERLAGE JE, Palese M, Birz S, Campo E, et al
    Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report.
    Leukemia. 2026 Jun 10. doi: 10.1038/s41375-026-02990.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum